Is AOD-9604 Legal? Global Status Guide
Category: Fat Loss · Tracked in 158 countries
29
Legal1
Research Only121
Grey Area3
Prescription4
BannedCan You Buy AOD-9604?
Whether you can buy AOD-9604 depends on your country. It is legal to purchase in 29 countries, including Jamaica, Dominican Republic, Bahamas, Trinidad and Tobago, Barbados, Cayman Islands, Aruba, Curacao, and 21 more. A prescription is required in 3 countries, including Australia, United Arab Emirates, New Zealand. It falls into a legal grey area in 121 countries (United States, Canada, Germany, France, Netherlands, Sweden, Norway, Denmark, and 113 more), where it may be available for research but not for human use. It is banned in 4 countries: Cuba, China, Singapore, Saudi Arabia.
Traveling with AOD-9604
Traveling internationally with AOD-9604 requires understanding local laws at your destination. Do not carry AOD-9604 into countries where it is banned (Cuba, China, Singapore, Saudi Arabia) — you could face serious legal consequences. In countries requiring a prescription (Australia, United Arab Emirates, New Zealand), carry a valid prescription or doctor's letter. Always declare pharmaceutical products at customs and check the latest regulations before traveling.
Need to calculate your AOD-9604 dosage? Use the AOD-9604 reconstitution calculator on peptide.locker
AOD-9604 Legal Status by Country (158)
| Country | Status | Rx Required | Schedule | Detail |
|---|---|---|---|---|
| Anguilla | Legal | No | Not Scheduled | Not scheduled. De facto unregulated. |
| Antigua and Barbuda | Legal | No | Not Scheduled | Not specifically regulated. |
| Aruba | Legal | No | Unregistered | Not specifically regulated. |
| Bahamas | Legal | No | Unregistered | Not specifically regulated. |
| Barbados | Legal | No | Unregistered | Not specifically regulated. |
| Bosnia and Herzegovina | Legal | No | Not Registered | Non-EU. Not registered. GH fragment. Research-label available. |
| British Virgin Islands | Legal | No | Not Scheduled | Not scheduled. De facto unregulated. |
| Cayman Islands | Legal | No | Unregistered | Not specifically regulated. |
| Costa Rica | Legal | No | Unregistered | Not specifically regulated. |
| Curacao | Legal | No | Unregistered | Not specifically regulated. |
| Dominica | Legal | No | Not Scheduled | Not specifically regulated. |
| Dominican Republic | Legal | No | Unregistered | Not specifically regulated. |
| Georgia | Legal | No | Not Registered | Non-EU. Not registered. GH fragment. Research-label available. |
| Grenada | Legal | No | Not Scheduled | Not specifically regulated. |
| Jamaica | Legal | No | Unregistered | Not specifically regulated. |
| Montenegro | Legal | No | Not Registered | Non-EU. Not registered. GH fragment. Research-label available. |
| Montserrat | Legal | No | Not Scheduled | Not scheduled. De facto unregulated. |
| North Macedonia | Legal | No | Not Registered | Non-EU. Not registered. GH fragment. Research-label available. |
| Papua New Guinea | Legal | No | Not Scheduled | Not regulated. Anti-obesity peptide not addressed in PNG law. No local market. |
| Samoa | Legal | No | Not Scheduled | Not regulated. No specific framework. |
| Serbia | Legal | No | Not Registered | Non-EU. Not registered. GH fragment. Research-label available. No specific regulation. |
| St Kitts and Nevis | Legal | No | Not Scheduled | Not specifically regulated. |
| St Lucia | Legal | No | Not Scheduled | Not specifically regulated. |
| St Vincent and the Grenadines | Legal | No | Not Scheduled | Not specifically regulated. |
| Tonga | Legal | No | Not Scheduled | Not regulated. No specific framework. |
| Trinidad and Tobago | Legal | No | Unregistered | Not specifically regulated. |
| Turks and Caicos | Legal | No | Not Scheduled | Not scheduled. De facto unregulated. |
| Ukraine | Legal | No | Not Registered | Non-EU. Not registered. GH fragment. Research-label available. |
| Vanuatu | Legal | No | Not Scheduled | Not regulated. No specific framework. |
| United Kingdom | Research Only | No | Not Scheduled | Not controlled. GH fragment 176-191. Legal for research. HGH itself IS Class C but fragments are not. |
| Algeria | Grey Area | No | Unregistered | Not specifically regulated. GH fragment not addressed. Import restrictions apply. |
| Andorra | Grey Area | No | Not Scheduled | Not authorized. Unauthorized medicinal product. |
| Angola | Grey Area | No | Unregistered | Not specifically regulated. GH fragment not addressed. |
| Argentina | Grey Area | No | Unregistered | Not specifically regulated. |
| Austria | Grey Area | No | Not Scheduled / Unauthorized | No EMA authorization. GH fragment. Research-label available. |
| Bahrain | Grey Area | No | Unregistered | Not specifically regulated. |
| Bangladesh | Grey Area | No | Not Scheduled | Not registered. Unauthorized medicinal product. |
| Belgium | Grey Area | No | Not Scheduled / Unauthorized | No EMA authorization. GH fragment. Research-label available. |
| Belize | Grey Area | No | Unregistered | Not specifically regulated. |
| Bolivia | Grey Area | No | Unregistered | Not specifically regulated. |
| Bonaire | Grey Area | No | Not Scheduled | Not scheduled. De facto unregulated. |
| Botswana | Grey Area | No | Unregistered | Not specifically regulated. GH fragment not addressed. |
| Brazil | Grey Area | No | Unregistered | Not specifically regulated. |
| Brunei | Grey Area | No | Not Scheduled | Not registered. Unauthorized medicinal product. |
| Bulgaria | Grey Area | No | Not Scheduled / Unauthorized | No EMA authorization. GH fragment. Research-label available. |
| Cambodia | Grey Area | No | Unregistered | Available through local peptide suppliers. GH fragments not restricted. |
| Cameroon | Grey Area | No | Unregistered | Not specifically regulated. GH fragment not addressed. |
| Canada | Grey Area | No | Not Scheduled (CDSA) | Named in Health Canada seizure notices. No DIN. Unauthorized drug. |
| Cape Verde | Grey Area | No | Unregistered | Not specifically regulated. GH fragment not addressed. |
| Chile | Grey Area | No | Unregistered | Not specifically regulated. |
| Colombia | Grey Area | No | Unregistered | Not specifically regulated. |
| Croatia | Grey Area | No | Not Scheduled / Unauthorized | No EMA authorization. GH fragment. Research-label available. |
| Cyprus | Grey Area | No | Not Scheduled | No marketing authorization. Unauthorized under EU pharmaceutical framework. |
| Czech Republic | Grey Area | No | Not Scheduled / Unauthorized | No EMA authorization. GH fragment. Research-label available. |
| Democratic Republic of Congo | Grey Area | No | Unregistered | Not specifically regulated. GH fragment not addressed. |
| Denmark | Grey Area | No | Not Scheduled / Unauthorized | No EMA authorization. GH fragment. Research-label available. |
| Ecuador | Grey Area | No | Unregistered | Not specifically regulated. |
| Egypt | Grey Area | No | Unregistered | Not specifically regulated. |
| El Salvador | Grey Area | No | Unregistered | Not specifically regulated. |
| Estonia | Grey Area | No | Not Scheduled / Unauthorized | No EMA authorization. GH fragment. Research-label available. |
| Ethiopia | Grey Area | No | Unregistered | Not specifically regulated. GH fragment not addressed by EFDA. |
| Fiji | Grey Area | No | Unregistered | Not registered. GH peptide fragments not specifically addressed. |
| Finland | Grey Area | No | Not Scheduled / Unauthorized | No EMA authorization. GH fragment. Research-label available. |
| France | Grey Area | No | Not Scheduled / Unauthorized | No EMA authorization. GH fragment. Research-label available. |
| French Guiana | Grey Area | No | Unauthorized Medicine | Not approved. French framework. |
| Germany | Grey Area | No | Not Scheduled / Unauthorized | No EMA authorization. GH fragment. Research-label available. |
| Ghana | Grey Area | No | Unregistered | Not specifically regulated. |
| Greece | Grey Area | No | Not Scheduled / Unauthorized | No EMA authorization. GH fragment. Research-label available. |
| Guatemala | Grey Area | No | Unregistered | Not specifically regulated. |
| Guyana | Grey Area | No | Unregistered | Not specifically regulated. |
| Honduras | Grey Area | No | Unregistered | Not specifically regulated. |
| Hong Kong | Grey Area | No | Unregistered | Not specifically regulated. |
| Hungary | Grey Area | No | Not Scheduled / Unauthorized | No EMA authorization. GH fragment. Research-label available. |
| Iceland | Grey Area | No | WADA S2 (peptide hormones); unauthorized medicine | WADA S2 classified (GH fragment). Postal import prohibited. Same framework as other WADA peptides. |
| India | Grey Area | No | Unregistered | Available from Indian suppliers. |
| Indonesia | Grey Area | No | Unregistered | Not specifically regulated. |
| Iran | Grey Area | No | Not Scheduled | Not registered. Unauthorized medicinal product. Import blocked by sanctions. |
| Iraq | Grey Area | No | Not Scheduled | Not registered. Could enter through informal channels. |
| Ireland | Grey Area | No | Not Scheduled / Unauthorized | No EMA authorization. GH fragment. Research-label available. |
| Israel | Grey Area | No | Unregistered | Not specifically regulated. |
| Italy | Grey Area | No | Not Scheduled / Unauthorized | No EMA authorization. GH fragment. Research-label available. |
| Ivory Coast | Grey Area | No | Unregistered | Not specifically regulated. GH fragment not addressed. |
| Japan | Grey Area | No | Unapproved Drug | Unapproved under PMD Act. |
| Jordan | Grey Area | No | Unregistered | Not specifically regulated. |
| Kenya | Grey Area | No | Unregistered | Not specifically regulated. No domestic market. |
| Kuwait | Grey Area | No | Unregistered | Not specifically regulated. |
| Laos | Grey Area | No | Unregistered | Not registered. GH peptide fragments not specifically addressed. |
| Latvia | Grey Area | No | Not Scheduled / Unauthorized | No EMA authorization. GH fragment. Research-label available. |
| Lebanon | Grey Area | No | Not Scheduled | Not registered. No specific framework. |
| Libya | Grey Area | No | Unregistered | Not specifically regulated. GH fragment not addressed. |
| Liechtenstein | Grey Area | No | Not Scheduled | No marketing authorization. Unauthorized under EEA framework. |
| Lithuania | Grey Area | No | Not Scheduled / Unauthorized | No EMA authorization. GH fragment. Research-label available. |
| Luxembourg | Grey Area | No | Not Scheduled | No marketing authorization. Unauthorized under EU framework. |
| Madagascar | Grey Area | No | Unregistered | Not specifically regulated. GH fragment not addressed. |
| Malawi | Grey Area | No | Unregistered | Not specifically regulated. GH fragment not addressed. |
| Malaysia | Grey Area | No | Unregistered | Not specifically regulated. |
| Maldives | Grey Area | No | Unregistered | Not registered. GH peptide fragments not specifically addressed. |
| Malta | Grey Area | No | Unauthorized Medicine | Not authorized. GH fragment not approved by EMA. Cannot be legally sold or imported. |
| Mauritius | Grey Area | No | Unregistered | Not specifically regulated. |
| Mexico | Grey Area | No | Unregistered | Available at some specialist suppliers and clinics. |
| Monaco | Grey Area | No | Not Scheduled | No marketing authorization. Unauthorized under French framework. |
| Morocco | Grey Area | No | Unregistered | No AMM. Not specifically regulated. |
| Mozambique | Grey Area | No | Unregistered | Not specifically regulated. GH fragment not addressed. |
| Myanmar | Grey Area | No | Unregistered | Available through drug shops. GH fragments not specifically restricted. |
| Namibia | Grey Area | No | Unregistered | Not registered. No domestic market. |
| Nepal | Grey Area | No | Unregistered | Not registered. GH peptide fragments not specifically addressed. |
| Netherlands | Grey Area | No | Not Scheduled / Unauthorized | No EMA authorization. GH fragment. Research-label available. |
| Nicaragua | Grey Area | No | Unregistered | Not specifically regulated. |
| Nigeria | Grey Area | No | Unregistered | Not specifically regulated. No domestic market. |
| Norway | Grey Area | No | Not Scheduled / Unauthorized | No EMA authorization. GH fragment. Research-label available. |
| Oman | Grey Area | No | Unregistered | Not specifically regulated. |
| Pakistan | Grey Area | No | Not Scheduled | Not registered. Unauthorized medicinal product. |
| Panama | Grey Area | No | Unregistered | Not specifically regulated. |
| Paraguay | Grey Area | No | Unregistered | Not specifically regulated. |
| Peru | Grey Area | No | Unregistered | Not specifically regulated. |
| Philippines | Grey Area | No | Unregistered | Not specifically regulated. |
| Poland | Grey Area | No | Not Scheduled / Unauthorized | No EMA authorization. GH fragment. Research-label available. |
| Portugal | Grey Area | No | Not Scheduled / Unauthorized | No EMA authorization. GH fragment. Research-label available. |
| Qatar | Grey Area | No | Unregistered | Not specifically regulated. |
| Romania | Grey Area | No | Not Scheduled / Unauthorized | No EMA authorization. GH fragment (hGH 176-191). Research-label available. |
| Russia | Grey Area | No | Unregistered | Not specifically regulated. |
| Rwanda | Grey Area | No | Unregistered | Not registered. No domestic market. |
| Saba | Grey Area | No | Not Scheduled | Not scheduled. De facto unregulated. |
| Saint Barthelemy | Grey Area | No | Unauthorized Medicine | Not approved. French framework. |
| Saint Martin (French) | Grey Area | No | Unauthorized Medicine | Not approved. French framework. |
| Senegal | Grey Area | No | Unregistered | Not registered. No domestic market. |
| Seychelles | Grey Area | No | Unregistered | Not registered. GH peptide fragments not specifically addressed. |
| Sint Eustatius | Grey Area | No | Not Scheduled | Not scheduled. De facto unregulated. |
| Sint Maarten | Grey Area | No | Not Scheduled | Not scheduled. De facto unregulated. |
| Slovakia | Grey Area | No | Not Scheduled / Unauthorized | No EMA authorization. GH fragment. Research-label available. |
| Slovenia | Grey Area | No | Not Scheduled / Unauthorized | No EMA authorization. GH fragment. Research-label available. |
| South Africa | Grey Area | No | Unregulated | Not specifically scheduled. HGH fragment 176-191. Available from research vendors. Not same regulatory treatment as full HGH (which is Schedule 5). Minimal enforcement attention. |
| South Korea | Grey Area | No | Unregistered | Not specifically regulated. |
| Spain | Grey Area | No | Not Scheduled / Unauthorized | No EMA authorization. GH fragment. Research-label available. |
| Sri Lanka | Grey Area | No | Unregistered | Not registered. GH peptide fragments not approved by reference authorities. |
| Suriname | Grey Area | No | Unregistered | Not specifically regulated. |
| Sweden | Grey Area | No | Not Scheduled / Unauthorized | No EMA authorization. GH fragment. Research-label available. |
| Switzerland | Grey Area | No | Not Scheduled / Unauthorized | No EMA authorization. GH fragment. Research-label available. |
| Taiwan | Grey Area | No | Unregistered | Not specifically regulated. |
| Tanzania | Grey Area | No | Unregistered | Not specifically regulated. |
| Thailand | Grey Area | No | Unregistered | Available at wellness clinics. |
| Tunisia | Grey Area | No | Unregistered | No MA. Not specifically regulated. |
| Turkey | Grey Area | No | Unregistered | Not specifically regulated. |
| Uganda | Grey Area | No | Unregistered | Not specifically regulated. GH fragment not addressed by NDA. |
| United States | Grey Area | No | Not Scheduled | On FDA Category 2 list. Cannot be compounded. Available from research vendors. Anti-obesity peptide (GH fragment). |
| Uruguay | Grey Area | No | Unregistered | Not specifically regulated. |
| US Virgin Islands | Grey Area | No | Not Scheduled | Same as US. FDA Category 2 listed. |
| Venezuela | Grey Area | No | Unregistered | Not specifically regulated. |
| Vietnam | Grey Area | No | Unregistered | Not specifically regulated. |
| Zambia | Grey Area | No | Unregistered | Not specifically regulated. GH fragment not addressed. |
| Zimbabwe | Grey Area | No | Unregistered | Not specifically regulated. GH fragment not addressed. |
| Australia | Prescription | Yes | Schedule 4 + Appendix D Item 5 | Individually named in Schedule 4 + Appendix D since 1 June 2015. Australian-developed peptide (Metabolic Pharmaceuticals). |
| New Zealand | Prescription | Yes | Unapproved (Rx Required) | Prescription medicine. |
| United Arab Emirates | Prescription | Yes | Clinic Prescribed | Clinic-administered only. |
| China | Banned | No | Unapproved Drug | Unauthorized for domestic use. |
| Cuba | Banned | No | State Controlled | State pharmaceutical monopoly via CECMED/BioCubaFarma. No private purchase/import permitted. |
| Saudi Arabia | Banned | No | Unauthorized | Unauthorized. |
| Singapore | Banned | No | Unapproved Health Product | Unapproved. Do not import. |
Data is researcher-verified but not legal advice. Regulations change frequently. Always verify with local authorities before purchasing, importing, or traveling with peptides. Last verified: 2026-02-28.